+1-518-621-2074 | US-Canada Toll Free Contact Us

U.S. Fertility Market to Expand at 4.07% CAGR between 2016 and 2020, Emergence of ART Boosts Market

about us

Published on : Feb 25, 2016

ALBANY, New York, Feb 25, 2016: ResearchMoz.us has recently announced the addition of a new market study, titled “Fertility Market in the US 2016-2020,” to its vast base of research reports. The study offers a comprehensive analysis of the fertility market in the U.S., estimating it to rise at a CAGR of 4.07% during the period from 2016 to 2020.

Over the previous few years, infertility has become a major concern in the U.S. The country is witnessing a decline in birth rates and infertility is one of the key reasons behind this. Taking this fact into consideration, the U.S. government has initiated a number of programs, such as encouraging the adoption of assisted reproductive technology (ART), to curb the rising rate of infertility among their citizens. The emergence of this technology has boosted the U.S. fertility market greatly in the recent times. 

Apart from this, the rising trend of postponing motherhood among women in the U.S. has increased the prevalence of infertility and other fertility-related issues among them, which has resulted in a remarkable rise of the U.S. fertility market.

Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=560799

The growing incidence of infertility among males in the country has also added significantly to the U.S. fertility market. However, the high cost associated with the treatment of fertility-related problems has restricted the demand for these treatments, limiting the growth of this market, says the research report.

As per the market study, hormonal imbalance, endometriosis, damaging of the fallopian tube, and cervical abnormalities are the key factors that lead to infertility among females, while low production or abnormal functioning or inadequate delivery of sperms are the main cause of infertility among males.

ART and infertility drugs are the two major types of treatments available in the U.S. infertility market. As of now, infertility drugs are more in demand compared to ART. However, technical advancement in ART has raised its efficiency, boosting the popularity of this technique. On account of its popularity, the ART segment is expected to lead the fertility treatment market over the forecast period, says the research report.

The competitive landscape prevalent in the U.S. fertility market has also been studied in this market report. It analyzes the company profiles of key players operating in this market to present the current market hierarchy.

According to the study, the fertility market in the U.S. is led by Merck, Cellcura, IntraMed, CooperSurgical Inc., and Ferring Pharmaceuticals. Other prominent market players mentioned in this report are Abbott Laboratories, Actavis, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, IKS International, INVO Bioscience, IVFtech, Novartis, Meditex, Ovascience, Sanofi, Pfizer, Vivus, Pantec Biosolutions, and Xytex Cryo Int.

Major companies functioning in this market are getting increasingly involved in mergers, acquisitions, and partnerships in a bid to strengthen their product portfolio and expand their reach to consumers, states the research report.

To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]